Free tool
FAERS Monitor: Favlyxa
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 220201 or its brand name (Favlyxa, Fluorouracil). Reports on generic versions are filed under their own applications.
Reports
77,573
Serious
0
0% of reports
Hospitalization
31,278
Death reported
0
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea7,076
- neutropenia5,294
- nausea5,063
- vomiting4,037
- off label use3,617
- neuropathy peripheral3,541
- fatigue3,319
- disease progression3,293
- pyrexia3,085
- thrombocytopenia3,036
- febrile neutropenia2,915
- anaemia2,610
- asthenia2,589
- drug ineffective2,238
- malignant neoplasm progression2,217
Reports by year received
View as table
| Year | Reports |
|---|
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,976,586 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| febrile neutropeniaSignal | 2,915 | 12.4 | 12.0 | 29,336 |
| neutropeniaSignal | 5,294 | 10.9 | 10.7 | 46,261 |
| disease progressionSignal | 3,293 | 7.7 | 7.5 | 18,867 |
| thrombocytopeniaSignal | 3,036 | 7.5 | 7.3 | 16,834 |
| malignant neoplasm progressionSignal | 2,217 | 6.0 | 5.7 | 9,029 |
| anaemiaSignal | 2,610 | 3.7 | 3.6 | 5,231 |
| diarrhoeaSignal | 7,076 | 3.0 | 2.9 | 9,587 |
| pyrexiaSignal | 3,085 | 2.4 | 2.3 | 2,615 |
| vomitingSignal | 4,037 | 2.3 | 2.3 | 3,139 |
| asthenia | 2,589 | 1.9 | 1.8 | 1,064 |
| nausea | 5,063 | 1.7 | 1.7 | 1,642 |
| fatigue | 3,319 | 1.2 | 1.1 | 73 |
| off label use | 3,617 | 1.1 | 1.1 | 49 |
| drug ineffective | 2,238 | 0.5 | 0.4 | 1,515 |
| neuropathy peripheral | 3,541 | 0.0 | 0.0 | 957,415 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.